{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:09:29Z","timestamp":1793286569464,"version":"4.5.0"},"reference-count":143,"publisher":"Oxford University Press (OUP)","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"DOI":"10.1093\/eurheartj\/ehu298","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:16:52Z","timestamp":1409012212000},"page":"3155-3179","source":"Crossref","is-referenced-by-count":439,"title":["Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)"],"prefix":"10.1093","volume":"35","author":[{"name":"Task Force Members","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"Ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Georg","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Document Reviewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,26]]},"reference":[{"key":"2026080919371526500_EHU298C1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C3","first-page":"781","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17300","article-title":"Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review","volume":"17","author":"Lane","year":"2013","journal-title":"Health Technol Assess"},{"key":"2026080919371526500_EHU298C8","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PloS One"},{"key":"2026080919371526500_EHU298C9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/europace\/euu008","article-title":"Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey","volume":"16","author":"Potpara","year":"2014","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/ stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C12","doi-asserted-by":"crossref","first-page":"e000382","DOI":"10.1161\/JAHA.113.000382","article-title":"New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with long-term follow-up: a Nationwide Study","volume":"3","author":"Bang","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026080919371526500_EHU298C13","first-page":"572","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective","volume":"106","author":"Faxon","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH11-08-0602","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe","volume":"106","author":"Huber","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jth.12140","article-title":"Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary","volume":"11","author":"Lip","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026080919371526500_EHU298C16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11239-012-0859-7","article-title":"Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation","volume":"35","author":"Mok","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"2026080919371526500_EHU298C17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/eurheartj\/ehq051","article-title":"Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting","volume":"31","author":"Tamburino","year":"2010","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/europace\/eut292","article-title":"Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey","volume":"15","author":"Lip","year":"2013","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C23","article-title":"Outcomes in patients with atrial fibrillation undergoing coronary artery stenting with a low-moderate CHA2DS2-VASc score: do they need anticoagulation?","author":"Mutuberria","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C24","first-page":"E864","article-title":"The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation undergoing coronary artery stenting study","volume":"82","author":"Schlitt","year":"2013","journal-title":"Cathet Cardiovasc Interv"},{"key":"2026080919371526500_EHU298C25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4244\/EIJV8I9A163","article-title":"Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents","volume":"8","author":"Pilgrim","year":"2013","journal-title":"EuroIntervention"},{"key":"2026080919371526500_EHU298C26","first-page":"170","article-title":"In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry","volume":"25","author":"Rubboli","year":"2013","journal-title":"J Invasive Cardiol"},{"key":"2026080919371526500_EHU298C27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH13-04-0351","article-title":"Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation","volume":"110","author":"Bernard","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C28","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C30","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3760\/cma.j.issn.0366-6999.20130359","article-title":"Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis","volume":"126","author":"Saheb","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"2026080919371526500_EHU298C31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2012.04.005","article-title":"Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study","volume":"125","author":"Donze","year":"2012","journal-title":"Am J Med"},{"key":"2026080919371526500_EHU298C32","first-page":"213","article-title":"Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation","volume":"29","author":"Ho","year":"2013","journal-title":"Can J Cardiol"},{"key":"2026080919371526500_EHU298C33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ageing\/afs121","article-title":"Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting","volume":"42","author":"Caballero","year":"2013","journal-title":"Age Ageing"},{"key":"2026080919371526500_EHU298C34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.amjcard.2011.10.004","article-title":"Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention","volume":"109","author":"Chan","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080919371526500_EHU298C35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.amjmed.2012.04.006","article-title":"Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes","volume":"125","author":"Lopes","year":"2012","journal-title":"Am J Med"},{"key":"2026080919371526500_EHU298C36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1253\/circj.CJ-11-1206","article-title":"Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry","volume":"76","author":"Lahtela","year":"2012","journal-title":"Circ J"},{"key":"2026080919371526500_EHU298C37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCINTERVENTIONS.112.968792","article-title":"Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?","volume":"5","author":"Ruiz-Nodar","year":"2012","journal-title":"Circ Cardiovasc Intervent"},{"key":"2026080919371526500_EHU298C38","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2012.02.042","article-title":"Comparison of frequency of major adverse events in patients with atrial fibrillation receiving bare-metal versus drug-eluting stents in their coronary arteries","volume":"110","author":"Fauchier","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080919371526500_EHU298C40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1160\/TH11-08-0524","article-title":"Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting","volume":"107","author":"Manzano-Fernandez","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C41","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.amjcard.2012.01.353","article-title":"Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry)","volume":"109","author":"Rubboli","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080919371526500_EHU298C42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention"},{"key":"2026080919371526500_EHU298C43","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Internal Med"},{"key":"2026080919371526500_EHU298C44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"Triple therapy\u2019 rather than \u2018triple threat\u2019: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4330\/wjc.v3.i11.367","article-title":"Adequate antiplatelet r\u00e9gimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention","volume":"3","author":"Brugaletta","year":"2011","journal-title":"World J Cardiol"},{"key":"2026080919371526500_EHU298C46","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1253\/circj.CJ-09-0880","article-title":"Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation","volume":"74","author":"Gao","year":"2010","journal-title":"Circ J"},{"key":"2026080919371526500_EHU298C47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jjcc.2009.12.014","article-title":"Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents","volume":"55","author":"Uchida","year":"2010","journal-title":"J Cardiol"},{"key":"2026080919371526500_EHU298C48","first-page":"936","article-title":"Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel","volume":"75","author":"Pasceri","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080919371526500_EHU298C49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1540-8183.2009.00468.x","article-title":"Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting","volume":"22","author":"Rubboli","year":"2009","journal-title":"J Interv Cardiol"},{"key":"2026080919371526500_EHU298C50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjcard.2009.03.053","article-title":"Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO])","volume":"104","author":"Gilard","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026080919371526500_EHU298C51","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/hrt.2009.167064","article-title":"Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study","volume":"95","author":"Sambola","year":"2009","journal-title":"Heart"},{"key":"2026080919371526500_EHU298C52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS Registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"key":"2026080919371526500_EHU298C53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1160\/TH13-08-0677","article-title":"Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy","volume":"110","author":"Marin","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C54","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1160\/TH12-08-0542","article-title":"The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation","volume":"109","author":"Azoulay","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1160\/TH13-06-0453","article-title":"Differences between ACC\/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes","volume":"110","author":"Huber","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C57","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ahj.2013.07.028","article-title":"Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial","volume":"166","author":"Sambola","year":"2013","journal-title":"Am Heart J"},{"key":"2026080919371526500_EHU298C58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(13)61521-4","article-title":"Antiplatelet therapy and anticoagulants","volume":"382","author":"Schlitt","year":"2013","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C59","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C60","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C63","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C65","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C66","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026080919371526500_EHU298C68","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C69","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001592","article-title":"Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials","volume":"2","author":"Mak","year":"2012","journal-title":"BMJ Open"},{"key":"2026080919371526500_EHU298C70","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C71","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C72","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjmed.2010.01.031","article-title":"Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?","volume":"123","author":"Lip","year":"2010","journal-title":"Am J Med"},{"key":"2026080919371526500_EHU298C74","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C75","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/VHRM.S49830","article-title":"Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment","volume":"9","author":"Clemens","year":"2013","journal-title":"Vasc Health Risk Manage"},{"key":"2026080919371526500_EHU298C76","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Buller","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","article-title":"Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial","volume":"35","author":"Mahaffey","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","article-title":"The Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study","volume":"128","author":"Connolly","year":"2013","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C80","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u2018real world\u2019 patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C81","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C82","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/eurheartj\/ehi135","article-title":"Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome","volume":"26","author":"Wenaweser","year":"2005","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C83","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C84","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/jama.2013.278787","article-title":"Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents","volume":"310","author":"Hawn","year":"2013","journal-title":"JAMA"},{"key":"2026080919371526500_EHU298C85","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C86","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.10-2719","article-title":"Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options","volume":"139","author":"Rubboli","year":"2011","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C87","author":"BRAVO-Investigators","year":"2011"},{"key":"2026080919371526500_EHU298C88","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C89","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C90","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026080919371526500_EHU298C91","doi-asserted-by":"crossref","first-page":"B218","DOI":"10.1016\/j.jacc.2011.10.836","article-title":"SAT-TAVI Investigators. SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: a randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"58","author":"Stabile","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C92","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2012.01.001","article-title":"ACCF\/AATS\/SCAI\/STS expert consensus document on transcatheter aortic valve replacement","volume":"59","author":"Holmes","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C93","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080919371526500_EHU298C94","first-page":"520","article-title":"Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement","volume":"28","author":"Webb","year":"2012","journal-title":"Can J Cardiol"},{"key":"2026080919371526500_EHU298C95","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C96","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12181-009-0183-4","article-title":"Positionspapier zur kathetergef\u00fchrten Aortenklappenintervention","volume":"3","author":"Figulla","year":"2009","journal-title":"Kardiologie"},{"key":"2026080919371526500_EHU298C97","first-page":"e523","article-title":"2008 Focused update incorporated into the ACC\/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"118","author":"Bonow","year":"2008","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/CIRCINTERVENTIONS.112.972869","article-title":"Bivalirudin versus heparin plus a glycoprotein IIb\/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials","volume":"5","author":"Ndrepepa","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080919371526500_EHU298C99","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C100","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4244\/EIJV8I12A209","article-title":"The 2011\u201312 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients","volume":"8","author":"Di Mario","year":"2013","journal-title":"EuroIntervention"},{"key":"2026080919371526500_EHU298C101","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa1114705","article-title":"Registry of transcatheter aortic-valve implantation in high-risk patients","volume":"366","author":"Gilard","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C102","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"New Engl J Med"},{"key":"2026080919371526500_EHU298C103","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C104","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1212\/WNL.0b013e318294b32d","article-title":"Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"2026080919371526500_EHU298C105","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4244\/EIJV9SSA3","article-title":"Guidelines on valvular heart disease in clinical practice","volume":"9","author":"Vahanian","year":"2013","journal-title":"EuroIntervention"},{"key":"2026080919371526500_EHU298C106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1540-8159.2010.02703.x","article-title":"Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios","volume":"33","author":"Ghanbari","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080919371526500_EHU298C107","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.hrthm.2010.02.018","article-title":"Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation","volume":"7","author":"Ahmed","year":"2010","journal-title":"Heart Rhythm"},{"key":"2026080919371526500_EHU298C108","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jacc.2009.12.056","article-title":"Dual antiplatelet therapy and heparin \u2018bridging\u2019 significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation","volume":"55","author":"Tompkins","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C109","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.hlc.2010.08.011","article-title":"Peri-procedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly","volume":"19","author":"Chow","year":"2010","journal-title":"Heart, Lung Circ"},{"key":"2026080919371526500_EHU298C110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.hrthm.2010.12.016","article-title":"Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial","volume":"8","author":"Cheng","year":"2011","journal-title":"Heart Rhythm"},{"key":"2026080919371526500_EHU298C111","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1540-8159.2011.03049.x","article-title":"No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure","volume":"34","author":"Li","year":"2011","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080919371526500_EHU298C112","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.hrthm.2011.10.010","article-title":"Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices","volume":"9","author":"Cano","year":"2012","journal-title":"Heart Rhythm"},{"key":"2026080919371526500_EHU298C113","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4070\/kcj.2012.42.8.538","article-title":"Antithrombotic or anti-platelet agents in patients undergoing permanent pacemaker implantation","volume":"42","author":"Lee","year":"2012","journal-title":"Korean Circ J"},{"key":"2026080919371526500_EHU298C114","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080919371526500_EHU298C115","first-page":"1110","article-title":"Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation","volume":"29","author":"Chen","year":"2013","journal-title":"Can J Cardiol"},{"key":"2026080919371526500_EHU298C116","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/ATVBAHA.109.199406","article-title":"Periprocedural anticoagulation management of patients with venous thromboembolism","volume":"30","author":"McBane","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080919371526500_EHU298C117","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1538-7836.2009.03685.x","article-title":"Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?","volume":"8","author":"Steib","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026080919371526500_EHU298C118","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11239-010-0470-8","article-title":"Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?","volume":"30","author":"Billett","year":"2010","journal-title":"J Thromb Thrombol"},{"key":"2026080919371526500_EHU298C119","doi-asserted-by":"crossref","DOI":"10.1016\/j.gie.2009.12.054","article-title":"Adverse events associated with anticoagulation therapy in the periendoscopic period","volume":"71","author":"Gerson","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"2026080919371526500_EHU298C120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.amjmed.2009.09.017","article-title":"Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals","volume":"123","author":"Jaffer","year":"2010","journal-title":"Am J Med"},{"key":"2026080919371526500_EHU298C121","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.921320","article-title":"Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio","volume":"121","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C122","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/europace\/eur038","article-title":"Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment","volume":"13","author":"Hakalahti","year":"2011","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C123","first-page":"403","article-title":"Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation","volume":"12","author":"Smoyer-Tomic","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026080919371526500_EHU298C124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.thromres.2011.09.031","article-title":"Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy","volume":"130","author":"Pini","year":"2012","journal-title":"Thromb Res"},{"key":"2026080919371526500_EHU298C125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1538-7836.2011.04572.x","article-title":"Predictors of major bleeding in peri-procedural anticoagulation management","volume":"10","author":"Tafur","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2026080919371526500_EHU298C126","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C127","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","article-title":"Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor","volume":"108","author":"Turpie","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C128","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes","volume":"59","author":"DeCaterina","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"2026080919371526500_EHU298C130","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/europace\/eut239","article-title":"Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"15","author":"Bin Abdulhak","year":"2013","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C131","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/europace\/eut241","article-title":"Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature","volume":"15","author":"Hohnloser","year":"2013","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C132","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","article-title":"Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry","volume":"63","author":"Lakkireddy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080919371526500_EHU298C133","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/europace\/eut232","article-title":"Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork\/European Heart Rhythm Association consensus conference","volume":"15","author":"Kirchhof","year":"2013","journal-title":"Europace"},{"key":"2026080919371526500_EHU298C134","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"2026080919371526500_EHU298C135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C136","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C137","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C138","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080919371526500_EHU298C139","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 Score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern Emerg Med"},{"key":"2026080919371526500_EHU298C141","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAMe-TT2R2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation","author":"Lip","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C142","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026080919371526500_EHU298C143","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/45\/3155\/70579514\/eurheartj_35_45_3155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/45\/3155\/70579514\/eurheartj_35_45_3155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T23:38:54Z","timestamp":1786318734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/35\/45\/3155\/2481294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,26]]},"references-count":143,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2014,8,26]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehu298","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,12,1]]},"published":{"date-parts":[[2014,8,26]]}}}